Puurs
Pfizer, BioNTech to limit delays of vaccine shipments to one week
Pfizer and BioNTech said Saturday they will limit the delays of their vaccine deliveries to just one week, after fears in Europe that shipments of the jabs could be slowed for up to a month. The US drugmaker and its German partner “have developed a plan that will allow the scale-up of manufacturing capacities in Europe and deliver significantly more doses in the second quarter,” they said in a joint statement. “As a result, our facility in Puurs, Belgium will experience a temporary reduction in the number of doses delivered in the upcoming week.” Pfizer and BioNTech pledged that deliveries would be back to the original schedule to the European Union from the week of January 25, with increased delivery from the week of February 15. “To accomplish this, certain modifications of production pr...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
